INTRODUCTION

Adult T-cell leukemia/lymphoma (ATL) is an aggressive lymphoproliferative disease caused by human T-cell leukemia virus type 1 (HTLV-1). Multi-agent chemotherapy can reduce ATL cells but frequently allows relapses within a short period of time. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is now a standard therapy for ATL in Japan as it can achieve long-term remission in approximately one-third of recipient ATL patients; however, it also has a risk of treatment-related mortality. Allo-HSCT often induces HTLV-1 Tax-specific cytotoxic T cells (CTL) as well as graft-versus-host (GVH) response in ATL patients. This observation led to development of a new therapeutic vaccine to activate Tax-specific CTL, anticipating anti-ATL effects without GVH response. The newly developed Tax-DC vaccine consists of autologous dendritic cells pulsed with Tax peptides corresponding to CTL epitopes that have been identified in post-allo-HSCT ATL patients. In a pilot study of Tax-DC therapy in three ATL patients after various initial therapies, two patients survived for more than 4 years after vaccination without severe adverse effects (UMIN000011423). The Tax-DC vaccine is currently under phase I trial, showing a promising clinical outcome so far. These findings indicate the importance of patients’ own HTLV-1-specific T-cell responses in maintaining remission and provide a new approach to anti-ATL immunotherapy targeting Tax. Although Tax-targeted vaccination is ineffective against Tax-negative ATL cells, it can be a safe alternative maintenance therapy for Tax-positive ATL and may be further applicable for treatment of indolent ATL or even prophylaxis of ATL development among HTLV-1-carriers.

1 Department of Immunotherapeutics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
2 Center for Advanced Medicine Innovation, Kyushu University, Fukuoka, Japan
3 Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan
4 Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan

Correspondence
Mari Kannagi, Department of Immunotherapeutics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Email: kann.impt@tmd.ac.jp

Funding information
Japan Agency for Medical Research and Development, (17ck0106371h0001, 17cm0106315h0002); Japan Cancer Society

Adult T-cell leukemia/lymphoma is an aggressive lymphoproliferative disease occurring in a small percentage of HTLV-1-infected individuals. There are four types of ATL: acute, lymphoma, chronic and smoldering. Among them, the former two are known to have a poor prognosis because of rapid progression, frequent relapse and severe immunosuppression. The prognosis of indolent ATL (smoldering and chronic ATL) varies widely among individuals. Katsuya et al categorized indolent ATL by the levels of remission.
sIL-2Ra in the serum and indicated the OS at 4 years to be 26.2%, 55.6% and 77.6% for low, intermediate and high-risk groups, respectively. Despite the presence of obvious hematological abnormalities, "watchful waiting" is usually recommended for indolent ATL, unless unfavorable prognostic factors appear, including elevated lactate dehydrogenase or blood urea nitrogen, or decreased albumin levels.\(^2\)

For acute- and lymphoma-type ATL, multi-agent chemotherapy and subsequent allo-HSCT are commonly used in Japan, achieving long-term remission in one-third of ATL cases.\(^3,5\) Recently, mogamulizumab\(^4\) and lenalidomide\(^6\) have also become available for acute- and lymphoma-type ATL. However, neither of these drugs are approved for indolent ATL yet. Combined IFN-\(\alpha\)/AZT therapy is widely used for ATL in other countries and is reported to be effective, especially for indolent ATL.\(^5,9\)

We recently developed a new therapeutic vaccine, Tax-DC, to activate HTLV-1 Tax-specific cytotoxic T cells (CTL), consisting of Tax peptide-pulsed autologous DC.\(^10\) This was based on the experimental findings that Tax-specific CTL showed anti-tumor effects in animal models of HTLV-1-infected tumors and the clinical observation that Tax-specific CTL were activated in ATL patients after allo-HSCT.\(^11\) A clinical study of the Tax-DC vaccine in a small number of ATL patients after various chemotherapy regimens suggests its potential role in achieving long-term remission.\(^10\) These findings indicate the importance of patients’ own immunity in maintenance of remission.

In this review, we focus on the Tax-targeted vaccine therapy, which provides a new approach to ATL therapy, which could be extended for treatment of indolent ATL or even ATL prophylaxis. We also discuss the mechanisms of immunosuppression, a key issue underlying ATL development, which is another important target for induction of anti-tumor immunity in therapeutic and prophylactic strategies against ATL.

### 2 CURRENTLY AVAILABLE ATL THERAPIES

For acute- and lymphoma-type ATL, multi-agent chemotherapy, mogamulizumab, lenalidomide and HSCT are currently available in Japan. The mechanisms of anti-ATL effects and influences on the host immunity of these therapies are summarized in Table 1.

For the last few decades since the discovery of ATL, various regimens of chemotherapy have been tried for ATL with limited success. The median survival time of ATL patients treated with the latest regimen of multi-agent chemotherapy (VCAP-AMP-VECp) was 12.7 months.\(^12\) Chemotherapy is effective in reducing ATL cells but allows frequent relapses.

Mogamulizumab is a humanized anti-CCR4 antibody that reduces ATL cells mainly through antibody-dependent cellular cytotoxicity by NK cells.\(^13\) Because Treg partly express CCR4, mogamulizumab also reduces Treg, which is of potential benefit for reducing immunosuppression.\(^14\) However, this is presumably a cause of the trend of severe adverse effects of HSCT in some patients who were previously treated with mogamulizumab.\(^15\) Median survival time of mogamulizumab for relapsed ATL patients was 13.7 months.\(^6\)

Lenalidomide has been used for multiple myeloma and was recently approved for ATL in Japan. Lenalidomide exerts its anti-tumor and immunomodulatory effects through binding with cereblon.\(^16\) Anti-tumor effects involve downregulation of transcription factors including IKZF1/3 and IRF4 in multiple myeloma,\(^17\) while immunomodulatory effects include activation of T- and NK cells that potentially support the anti-tumor immune response.\(^18\) Median survival time for lenalidomide in relapsed or recurrent ATL patients was 20.3 months.\(^7\)

Anti-ATL effects of IFN-\(\alpha\)/AZT combination therapy were first reported in 1995,\(^8,9\) and this regimen has been used for ATL patients in several countries, although it is not yet approved in

### TABLE 1 Mechanisms of currently available ATL therapies and Tax-DC vaccine

| Mechanism of anti-ATL effect | Effects on host immune system | Adverse effects |
|------------------------------|------------------------------|----------------|
| **Chemotherapy**             | Induction of cell death in dividing cells | Immune suppression | Cytoopenia |
| **Mogamulizumab**            | Killing of CCR4\(^4\) cells through ADCC by NK cells\(^13\) | Reduction of Treg | Infusion reactions, skin rash\(^6\) |
| **Lenalidomide**             | Downregulation of IKZF1/3, IRF4 and so forth by binding cereblon (multiple myeloma)\(^16,17\) | Enhancement of T-cell and NK cell activity\(^18\) | Cytoopenia\(^7\) |
| **IFN-\(\alpha\)/AZT**        | Activation of p53 pathway and suppression of Tax expression\(^20\) | Unknown | Cytoopenia\(^6,21\) |
| **Allo-HSCT**                | Elimination of recipient hematopoietic cells | Induction of GVH and Tax-specific CTL responses\(^25\) | GVHD |
| **Tax-DC vaccine**           | Killing of HTLV-1-infected cells | Activation of Tax-specific CTL response\(^10\) | Fever, skin rash\(^10\) |

ADCC, antibody-dependent cell-mediated cytotoxicity; allo-HSCT, allogeneic hematopoietic stem cell transplantation; ATL, adult T-cell leukemia/lymphoma; AZT, azidothymidine; CCR4, C-C chemokine receptor 4; CTL, cytotoxic T cells; DC, dendritic cells; GVH, graft-versus-host; GVHD, graft-versus-host disease; IKZF1/3, IKAROS family zinc finger 1 and 3; IRF4, interferon regulatory factor 4; NK, natural killer; Treg, regulatory T cells.

\(^4\)Reported in multiple myeloma.
Japan. The reported 5-year OS rates for IFN-α/AZT were 28%, 0% and 100% for acute, lymphoma and indolent types of ATL, respectively. Mechanisms of anti-ATL effects of IFN-α/AZT therapy include suppression of Tax expression and activation of the p53 pathway. However, IFN-α/AZT therapy frequently allows relapse of ATL after cessation of treatment.

To overcome the frequent relapses in aggressive types of ATL, allo-HSCT has been used for ATL patients combined with multi-agent chemotherapy in Japan, although early attempts at autologous HSCT in ATL patients were unsuccessful. In a retrospective analysis of 386 ATL cases treated with allo-HSCT, the 3-year OS was 33%, while allo-HSCT also caused treatment-related mortality in a similar number of patients. The reduced intensity conditioning regimens of allo-HSCT slightly improved the treatment-related mortality, while the survival curve still rapidly declined in the first 1-2 years, before reaching a plateau.

In allo-HSCT, the hematopoietic system of a recipient ATL patient is replaced with donor-derived hematopoietic cells. GVH response is the main anti-tumor mechanism of allo-HSCT, where the GVH responder T cells eliminate residual ATL cells together with other recipient cells. However, GVH response also causes GVH disease that can be fatal. Therefore, immunosuppressants are required for some time after allo-HSCT. After hematopoietic chimerism is established, the newly constituted system of T-cell tolerance begins to control the GVH response. In addition, activation of CD8+ HTLV-1 Tax-specific CTL is often observed in ATL patients following allo-HSCT, especially after removal of immunosuppressants. This is likely to be a result of de novo T-cell responses by the donor-derived immune system against Tax-expressing cells in the recipient tissues. Although Tax protein is usually undetectable in PBMC.

**FIGURE 1** Possible dynamics of human T-cell leukemia virus type 1 (HTLV-1)-infected cell clones during adult T-cell leukemia/lymphoma (ATL) development and autologous hematopoietic stem cell transplantation (allo-HSCT). Asymptomatic HTLV-1 carriers possess multiple HTLV-1-infected cell clones. Impairment of Tax-specific cytotoxic T cells (CTL) allows expansion of the pool of HTLV-1-infected cell clones (A), while it is controlled in the presence of intact Tax-specific CTL that survey Tax-expressing infected cells (B). At the onset of ATL, one or several HTLV-1-infected clones expand (C). Upon intensive chemotherapy, proliferating malignant ATL cells die (D), but the residual original ATL clones or secondary dominant clones proliferate again at relapse (E). When allo-HSCT is performed, graft-versus-host (GVH) and HTLV-1-specific T-cell responses occur, and recipient hematopoietic cells are eliminated together with residual ATL cells (F). After hematopoietic chimerism is established, Tax-specific CTL survey newly HTLV-1-infected donor-derived cells, contributing to the maintenance of remission (G).
by serological means in HTLV-1-infected individuals, activation of Tax-specific CTL in ATL patients after allo-HSCT demonstrates the presence of Tax expression in vivo at levels detectable by CTL.

Analysis of Tax-specific CTL in ATL patients after allo-HSCT identified dominant CTL epitopes to be restricted to HLA-A2, -A24 or -A11, respectively. These CTL epitopes are also found in HAM/TSP patients and asymptomatic HTLV-1-carriers, indicating that these epitopes are commonly recognized by CTL as an anti-viral immune response irrespective of disease.

4 | ATL RELAPSE AND ITS PREVENTION BY ALLO-HSCT

It is unclear why ATL relapses so frequently in a short period of time after chemotherapy. This may be related to the fact that HTLV-1-infected individuals possess numerous HTLV-1-infected clones, although most of them are not yet malignant (Figure 1). In asymptomatic HTLV-1-carriers with intact HTLV-1-specific T-cell responses, the immune surveillance system eliminates infected clones expressing viral antigens to some extent. However, under impaired HTLV-1-specific T-cell responses, the infected clones have greater chances of survival and evolution. Among such HTLV-1-infected clones, the dominant malignant clones proliferate during ATL development. After initial chemotherapy, only proliferating cells are eliminated. However, there remain numerous HTLV-1-infected clones. At relapse, the residual original ATL clone or secondary malignant clones may proliferate. The presence of a pool of HTLV-1-infected clones with various proliferation capacities and frequent acquisition of drug resistance is assumed to be a reason for such frequent ATL relapse. This scenario is consistent with previous reports that the dominant ATL clones sometimes change during the disease course and also between tissues.

In contrast, allo-HSCT eradicates recipient-derived cells irrespective of HTLV-1 infection or their capacity to proliferate. Allogeneic HSCT induces GvH response that is supposed to eliminate the residual ATL cells. Tax-specific CTL that are often activated after allo-HSCT may also partly contribute to GVL effect. Tax-specific CTL seem to remain in the long term as memory T-cells and potentially act as an immune surveillance system on newly HTLV-1-infected donor-derived clones after hematopoietic chimerism is established (Figure 1).

5 | TAX-TARGETED THERAPEUTIC VACCINE

The findings in ATL patients after allo-HSCT led to the hypothesis that a vaccine to activate Tax-specific CTL may induce long-term remission in ATL patients without GVHD. Our previous study using a rat model indicated that a vaccine using Tax peptide corresponding to the major epitope of CDB Tax-specific CTL induced tumor eradication, when appropriate adjuvant was used. To overcome the severe immunosuppression in ATL patients, we chose autologous monocyte-derived DC matured in vitro as an adjuvant for Tax-specific CTL vaccine. These DC were pulsed with Tax peptides corresponding to the major Tax-specific CTL epitopes previously identified in post-HSCT ATL patients (Figure 2).

In a small pilot study, the Tax-DC vaccine was administrated s.c. to three ATL patients in stable condition after initial therapies, but who could not receive allo-HSCT for various reasons. After three inoculations with Tax-DC vaccine, Tax-specific CTL were clearly activated in these patients without severe adverse effects. A long-term clinical follow up found that two of three patients survived for more than
TABLE 2  Clinical outcomes of the pilot study of Tax-DC vaccine therapy in ATL patients

| Disease status at enrollment | Patient 1 | Patient 2 | Patient 3 |
|-----------------------------|----------|----------|----------|
| SD                          | PR       | PR       |
| PR                          |          |          |
| PR                          |          |          |

Clinical response after vaccination

| 8 wk | Patient 1 | PR | SD | PR |
|------|-----------|----|----|----|
| 6 mo | Patient 2 | PR | PD | CR |

Long-term clinical outcomes

| TTNT | 53 mo | 15 mo | >5 y |
|------|-------|-------|------|
| Survival | 60 mo | 23 mo | >5 y |

ATL, adult T-cell leukemia/lymphoma; CR, complete remission; PD, progressive disease; PR, partial remission; SD, stable disease; TTNT, time to next therapy.

*Three patients with acute ATL were enrolled in the pilot study of Tax-DC vaccine at least 1 mo after previous therapies.*

*Long-term clinical outcome represents time after enrollment in the study.*

4 years after vaccination (Table 2). Patient 1 maintained PR without additional therapy for 4 years before exacerbation with lymph node swelling that was easily controlled by chemotherapy. However, this patient subsequently suffered repeated infections and died 5 years after vaccination. Patient 2 initially showed stable disease with improved performance status but relapsed at 6 months with lymphoma lacking the ability of viral expression and died 23 months after vaccination, suggesting an ATL clone without Tax expression escaped the host immunity. Patient 3 survived for longer than 5 years after vaccination and remains alive in CR.

The Tax-DC vaccine is currently in a phase I clinical trial, in which an additional three ATL patients treated with Tax-DC vaccine with the same regimen as the pilot study have remained in CR for at least 2 years. Although the effectiveness of Tax-DC vaccination remains to be confirmed by a phase II study, the clinical outcomes of these studies indicate that Tax-specific CTL may contribute considerably to maintenance of remission in ATL patients unless Tax-negative ATL clones emerge at relapse.

6  | TAX EXPRESSION IN ATL CELLS IN VIVO

Expression levels of Tax in vivo have been controversial. Despite the presence of HTLV-1 antibodies and Tax-specific CTL responses in many HTLV-1-infected individuals, viral proteins are undetectable in freshly isolated PBMC by serological means, raising skepticism around the significance of a Tax-targeted immunotherapy.

There are at least two types of ATL that can be separated by the ability of primary ATL cells to express HTLV-1 antigens. In nearly half of ATL cases, HTLV-1 antigens can be spontaneously induced after short-term culture. 4 In the remaining ATL cases, ATL cells do not express HTLV-1 antigens even after culture in vitro.

In the former, ATL cells retain the ability to express Tax. A similar reversible type of suppression can be reproduced in vitro by coculturing IL-2-dependent HTLV-1-infected cells with stromal cells, in which type I IFN responses occur. 5 Soluble type I IFN also suppresses HTLV-1 expression. IFN-stimulated genes such as PKR contribute to IFN-mediated suppression of Tax expression primarily at the post-transcriptional level. 6 This is consistent with the fact that pX mRNA is barely detectable in primary ATL cells despite undetectable Tax protein. 7 Thus, HTLV-1 expression in ATL cells in these cases is not absolutely silent. It remains unclear how Tax-specific CTL control ATL cells with such low levels of viral antigen in vivo. One possibility is the sensitivity of Tax-specific CTL, which can recognize much smaller amounts of antigen than those detectable by flow cytometry. 8 It is also conceivable that Tax-specific CTL may eliminate small numbers of Tax-expressing cells that are critical for the growth of the majority of ATL cells. Alternatively, ATL cells may express Tax for only a short period. 9

In contrast, ATL cells failing to express Tax cannot be a direct target of Tax-specific CTL. Genetic alteration and epigenetic silencing of HTLV-1 proviruses in ATL cells have been reported in such cases of ATL. 10 As these alterations are presumed to increase as the disease stage advances, Tax-targeting vaccines could be more effective in the earlier stages.
could also be a target for CTL. However, experimentally induced HBZ mRNA expression. In ATL cases, induced CTL may be cancer/testis antigens, as NY-ESO-1 mRNA is expressed in 61.4% of ATL cases. In advanced stages of the disease, this may be partly attributed to the generalized immunosuppression. However, impairment in the Tax-specific CTL response is also observed in early stages of ATL and even in a minor population of asymptomatic HTLV-1 carriers. In these individuals, the immunosuppression is selective against HTLV-1-specific responses, as CTL responses against other pathogens such as cytomegalovirus are comparable with HTLV-1-negative healthy individuals. There are several possible mechanisms of immunosuppression in ATL. First, immune tolerance resulting from newborn infection or oral infection through the mother’s milk may occur. Induction of HTLV-1-specific T-cell tolerance is well established in a rat model of oral HTLV-1 infection, which partly explains the epidemiological finding that ATL preferably develops from individuals infected through the vertical route. Second, T-cell exhaustion due to persistent viral infection is possible, as improvement of Tax-specific

### Table 3: Vaccine studies to induce HTLV-1-specific T-cell responses in animal models

| Antigen | Adjunct | Animal model | Induced immune response | Anti-HTLV-1/ATL effect in vivo | Reference |
|---------|---------|--------------|-------------------------|-------------------------------|-----------|
| Expression vector containing wild type or mutant Tax cDNA | None | Uninfected rats | Tax-specific CTL | Adoptively transferred CTL eradicated HTLV-1-infected lymphoma in nude rats | Ohashi et al[54] |
| Epitope peptide of Tax-specific CTL from rats | CpG-ODN | Uninfected rats | Tax-specific CTL | Adoptively transferred CTL eradicated HTLV-1-infected lymphoma in nude rats | Hanabuchi et al[52] |
| Multivalent peptide consisting of three Tax peptides (tri-Tax) of HLA-A*0201-restricted CTL epitopes with TT3 | Nor-MDP in squalene: arlacel A | Uninfected HLA-A*0201-Tg mice | CTL responses to each intended epitope | Reduction of viral replication after challenge with Tax-expressing recombinant vaccinia virus infection | Sundaram et al[57] |
| Envelope epitope peptide linked to MVF and multivalent tri-Tax epitope peptide | None | Uninfected squirrel monkeys | Antibody and T-cell responses | Protection of HTLV-1 infection in one of two monkeys after challenge with HTLV-1 infection | Kazanji et al[58] |
| HBc chimeric particle incorporating the HLA-A*0201-restricted HTLV-1 Tax-epitope | None | Uninfected HLA-A*0201-Tg mice | Tax 11-19-specific CTL | N.S. | Kozako et al[59] |
| Oligomannose-coated liposomes encapsulating Tax 11-19 peptide | None | Uninfected HLA-A*0201-Tg mice | Tax 11-19-specific CTL | N.S. | Kozako et al[60] |
| Tax 11-19 peptide with tetanus helper peptide | Incomplete Freund’s adjuvant | Uninfected HLA-A2.1/CD11c-DTR-Tg mice | Tax-specific CTL | N.S. | Sagar et al[61] |
| Recombinant vaccinia viruses expressing HBZ or Tax | None | Uninfected mice, HTLV-1-infected monkeys | HBZ or Tax-specific CTL | Adoptive transfer of HBZ-specific CTL increased survival of mice inoculated with HBZ-Tg mouse-derived lymphoma cells | Sugata et al[62] |
| Lentiviral vector encoding Tax, HBZ, p12, p30 | None | Uninfected mice and rats | Cellular immune response | N.S. | Revaud et al[63] |
| Epitope peptide of Tax-specific CTL from rats | Dendritic cells | Orally HTLV-1-infected rats | Tax-specific CTL | Reduction of HTLV-1 proviral load | Ando et al[65] |

CTL, cytotoxic T cells; DTR, diphtheria toxin receptor; HBc, hepatitis B virus core; HBZ, HTLV-1 basic leucine zipper; HLA, human leukocyte antigen; HTLV-1, human T-cell leukemia virus type 1; MVF, promiscuous T-helper cell epitope from measles virus fusion protein; N.S., not shown; Nor-MDP, N-acetylglucosamine-3-acetyl-L-Lalanyl-D-isoglutamine (muramyl dipeptide derivative); ODN, oligodeoxynucleotides; Tg, transgenic; TT3, promiscuous T-helper epitope from tetanus toxoid.

### 7 | Control of immunosuppression as a therapeutic option

Tax-specific CTL are mostly undetectable or dysfunctional in ATL patients. In advanced stages of the disease, this may be partly attributed to the generalized immunosuppression. Additional candidate target antigens for anti-ATL vaccine to induce CTL may be cancer/testis antigens, as NY-ESO-1 mRNA is expressed in 61.4% of ATL cases. It has been reported that HBZ could also be a target for CTL. However, experimentally induced HBZ-specific CTL hardly react with HTLV-1-infected cells or PBMC from HTLV-1-infected individuals, suggesting the scarcity of HBZ antigen presentation in HTLV-1-infected cells despite abundant HBZ mRNA expression.
CTL function by blockade of PD-1/PD-L1 interaction has been reported. PD-1/L1 is expressed on ATL cells in 7.4% of ATL cases, and alteration of this gene is frequently found in ATL cells. Third, IL-10, an immunosuppressive/anti-inflammatory cytokine, is elevated in the serum of ATL patients. IL-10 also promotes proliferation of HTLV-1-infected cells, suggesting its active role in leukemogenesis.

Because restoration of Tax-specific CTL functions by Tax-DC vaccine seems essential to maintain remission in ATL patients, mitigation of immunosuppression is an important factor in anti-ATL therapy. In this regard, mogamulizumab and lenalidomide may be helpful because they reduce Treg and enhance T-cell immunity, respectively. Although these effects are not antigen-specific, mogamulizumab and lenalidomide may further enhance Tax-specific CTL responses when combined with Tax-targeted vaccine. Immune checkpoint inhibitors may also restore Tax-specific T-cell responses, although care should be taken as they may potentially restore other unwanted autoimmune responses. A recent report indicated that nivolumab unexpectedly promoted ATL progression in indolent ATL, suggesting that the PD-1/PD-L1 system may still mediate a negative signal to ATL cells at indolent stages. Because ATL cells are a source of IL-10, decreasing ATL cells by various therapies may reduce IL-10 levels, thus alleviating some immunosuppression.

**8 | TAX-TARGETED VACCINE AS A POTENTIAL EARLY AND/OR PROPHYLACTIC THERAPY**

There is no approved therapy for indolent ATL in Japan. Intensive chemotherapy may not be suitable, as it induces immunosuppression. Chemotherapy is one of the factors for worse prognosis in indolent ATL. IFN-α/AZT is effective for indolent ATL, but requires continuous medication, as cessation of IFN-α/AZT allows relapse. Because Tax-silencing is presumed to be less frequent in earlier stages, a Tax-targeting vaccine may be a good candidate to treat indolent ATL.

It is also worth considering the use of Tax-targeted vaccination for disease prevention in HTLV-1 carriers at high risk of ATL. In a rat model of oral HTLV-1 infection, HTLV-1-specific T-cell tolerance was established with higher PVL than in rats infected through other routes, resembling the situation in HTLV-1 carriers with impaired CTL responses. This was resolved by Tax-DC vaccination, resulting in activation of Tax-specific CTL responses and reduced HTLV-1 PVL (Figure 3). This observation supports the idea of prophylactic use of Tax-targeted vaccines in HTLV-1 carriers with impaired Tax-specific CTL responses.

Although it has shown promise, the prototype Tax-DC vaccines are available only for patients possessing HLA-A2, -A24 and -A11 alleles because of the HLA restriction of the CTL, and so further development is encouraged. Various types of vaccines have been reported to induce HTLV-1-specific T-cell response using animal models (Table 3). It should be taken into consideration, however, that HTLV-1 causes not only ATL but also inflammatory diseases such as HAM/TSP. It is unknown whether the responses caused by CTL and/or adjuvants may produce pathogenic inflammation. To develop a disease-preventive vaccine, it is important to define the HTLV-1-infected population at high risk of ATL.

**9 | CONCLUSION**

In conclusion, the Tax-DC vaccine study provides a new concept in ATL therapy that invokes the patient's own immunity, particularly Tax-specific CTL, following only a short course of vaccination. These CTL...
contribute to long-lasting remission by continuously surveying HTLV-1-infected cells, although the CTL become ineffective when Tax-negative ATL cells proliferate in advanced stages. In addition, because of the limited toxicity, the timing of the Tax-targeted vaccine therapy may potentially be shifted to earlier stages of ATL (Figure 4), which may contribute to prophylactic strategies against ATL in the future.

ACKNOWLEDGMENTS

We thank Gillian Campbell, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. The studies described here were partly supported by grants from Japan Agency for Medical Research and Development (17ck0106371h0001, 17cm0106315h0002) and Japan Cancer Society.

CONFLICT OF INTEREST

The authors declare no conflicts of interest for this article.

ORCID

Mari Kannagi https://orcid.org/0000-0002-3433-2658

REFERENCES

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481-492.
2. Shimoyma M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
3. Katsuya H, Shimokawa M, Ishitsuka K, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130:39-47.
4. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15-20.
5. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369-1376.
6. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837-842.
7. Ishida T, Fujiwara H, Nosaka T, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086-4093.
8. Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744-1748.
9. Hermine O, Bouscary D, Gessain A, et al. Identification of two novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2004;10:7529-7539.
10. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110:17945-17950.
11. Lopez-Girona A, Mendy D, Ito T, et al. Cerebrolysin is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326-2335.
12. Harashima N, Tanosaki R, Shimizu Y, et al. Identification of cytotoxic peptide sequences recognized by patient-specific CD8+ T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. J Virol. 2007;81:2098-2107.
13. Okamura J, Tanosaki R, Igarashi M, et al. Novel multi-peptide- and multi-color-flow cytometric analysis in a minor population of asymptomatic human T-cell leukemia virus type 1-carriers. Retrovirology. 2011;8:100.
29. Ikeda K, Oka M, Yamada Y, et al. Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung resistance-protein (LRP) genes. Int J Cancer. 1999;82:599-604.
30. Iwatsuki K, Inoue F, Takigawa M, et al. Exchange of dominant lymphoid cell clones in a patient with adult T-cell leukemia/lymphoma. Acta Derm Venereol. 1990;70:49-52.
31. Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood. 1997;89:948-956.
32. Hanabuchi S, Ohashi T, Koya Y, et al. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: peptide-induced T-cell immunity. J Natl Cancer Inst. 2001;93:1775-1783.
33. Nagayama H, Sato K, Morishita M, et al. Results of a phase I clinical study using autologous tumour lystate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res. 2003;13:521-530.
34. Kurihara K, Harashima N, Hanabuchi S, et al. Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer. 2005;114:257-267.
35. Kinpara S, Hasegawa A, Utsunomiya A, et al. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol. 2009;83:5101-5108.
36. Kinoshita T, Shimoyama M, Tobinai K, et al. Detection of mRNA for the tax1/rev1 gene of human T-cell leukemia virus type 1 in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc Natl Acad Sci USA. 1989;86:5620-5624.
37. Suzuki S, Masaki A, Ishida T, et al. Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma. Cancer Sci. 2012;103:1764-1773.
38. Mahgoub M, Yasunaga JI, Iwami S, et al. Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proc Natl Acad Sci USA. 2018;115:E1269-E1278.
39. Takeda S, Maeda M, Morikawa S, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004;109:559-567.
40. Nishikawa H, Maeda Y, Ishida T, et al. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. J Infect Dis. 2010;203:529-536.
41. Rowan AG, Suemori K, Fujiwara H, et al. Cytotoxic T lymphocyte lysis of HTLV-1 infected cells is limited by weak HBZ protein expression, but non-specifically enhanced on induction of Tax expression. Retrovirology. 2014;11:116.
42. Suemori K, Fujiwara H, Ochi T, et al. HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes. J Gen Virol. 2009;90:1806-1811.
43. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA. 2006;103:720-725.
44. Hasegawa A, Ohashi T, Hanabuchi S, et al. Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response. J Virol. 2003;77:2956-2963.
45. Kozako T, Yoshimitsu M, Fujihara H, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23:375-382.
46. Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer. 1990;45:237-243.
47. Kozako T, Yoshimitsu M, Fujihara H, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23:375-382.
48. Miyoshi H, Kiyasu J, Kato T, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood. 2016;128:1374-1381.
49. Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature. 2016;534:402-406.
50. Inagaki A, Ishida T, Ishii T, et al. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer. 2006;118:3054-3061.
51. Kagi D, Demontis MA, Ramos JC, Taylor GP. Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T-lymphotropic virus type 1 infection. PLoS Pathog. 2018;14:e1006861.
52. Sawada L, Nagano Y, Hasegawa A, et al. IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type 1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017;13:e1006597.
53. Ratner L, Waldmann TA, Janakiram M, Bramer JE. Rapid progression of adult T-cell leukemia/lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378:1947-1948.
54. Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337-4343.
55. Ando S, Hasegawa A, Murakami Y, et al. HTLV-1 tax-specific CTL epitope-pulsed dendritic cell therapy reduces proviral load in infected rats with immune tolerance against tax. J Immunol. 2017;198:1210-1219.
56. Ohashi T, Hanabuchi S, Kato H, et al. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol. 2000;74:9610-9616.
57. Sundaram R, Lynch MP, Rawale S, et al. Protective efficacy of multiple epitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus. J Acquir Immune Defic Syndr. 2004;37:1329-1339.
58. Kazanji M, Heraldum JA, Merien F, et al. Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus). J Gen Virol. 2006;87:1331-1337.
59. Kozako T, Fukuda K, Hirata S, et al. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia. Mol Immunol. 2009;47:606-613.
60. Kozako T, Hirata S, Shimizu Y, et al. Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant. FEBS J. 2011;278:1358-1366.
61. Sagar D, Masih S, Schell T, et al. In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine. Vaccine. 2014;32:3274-3284.
62. Sugata K, Yasunaga J, Mitobe Y, et al. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood. 2015;126:1095-1105.
63. Revaud D, Bejanaru A, Louisseau F, et al. Development of an anti-HTLV-1 vaccine for the treatment of adult T-cell leukemia/lymphoma. Blood. 2015;126:4010. (Meeting abstract)

How to cite this article: Kanna A, Hasegawa A, Nagano Y, Iino T, Okamura J, Suehiro Y. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy. Cancer Sci. 2019;110:849-857. https://doi.org/10.1111/cas.13948